Patents by Inventor Kevin Love

Kevin Love has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11937355
    Abstract: A dimmer switch system for dimming a load includes a master dimmer structured to be electrically connected to a power source and the load and to control dimming of the load by regulating power provided from the power source to the load, and at least one accessory dimmer structured to be electrically connected to the master dimmer via a traveler conductor. The master dimmer is structured to generate a first control signal on the traveler conductor to indicate a type of the master dimmer, and the at least one accessory dimmer is structured to selectively enable or disable one or more functions of the at least one accessory dimmer based on the type of the master dimmer.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: March 19, 2024
    Assignee: EATON INTELLIGENT POWER LIMITED
    Inventors: Sumeet T. Raghavani, Grayling Love, Ahmed El-Gayyar, Kevin Zhong, Saivaraprasad Murahari
  • Patent number: 11819550
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: November 21, 2023
    Assignee: EAGLE BIOLOGICS, INC.
    Inventors: Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 11471479
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of polysaccharides and nucleic acids have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight polysaccharides and nucleic acids, and viscosity-lowering agents.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: October 18, 2022
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 11420933
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: August 23, 2022
    Assignee: Novartis AG
    Inventors: Luis Brito, Delai Chen, Gabriel Gamber, Andrew Geall, Kevin Love, Thomas Zabawa, Frederic Zecri
  • Patent number: 11013696
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R3, n, p, L1 and L2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: May 25, 2021
    Assignee: Novartis AG
    Inventors: Luis Brito, Delai Chen, Gabriel Grant Gamber, Andrew Geall, Kevin Love, Thomas Zabawa, Frederic Zecri
  • Publication number: 20210085792
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 25, 2021
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20210078936
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Application
    Filed: November 25, 2020
    Publication date: March 18, 2021
    Inventors: Luis BRITO, Delai CHEN, Gabriel GAMBER, Andrew GEALL, Kevin LOVE, Thomas ZABAWA, Frederic ZECRI
  • Publication number: 20210038718
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
    Type: Application
    Filed: October 9, 2020
    Publication date: February 11, 2021
    Inventors: Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20210030877
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.
    Type: Application
    Filed: October 19, 2020
    Publication date: February 4, 2021
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 10906867
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: February 2, 2021
    Assignee: Novartis AG
    Inventors: Luis Brito, Delai Chen, Gabriel Grant Gamber, Andrew Geall, Kevin Love, Thomas Zabawa, Frederic Zecri
  • Patent number: 10849977
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: December 1, 2020
    Assignee: EAGLE BIOLOGICS, INC.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 10821183
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: November 3, 2020
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 10821184
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: November 3, 2020
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20200330501
    Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.
    Type: Application
    Filed: May 5, 2020
    Publication date: October 22, 2020
    Applicant: Massachusetts Institute of Technology
    Inventors: Yizhou Dong, Kevin Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
  • Patent number: 10646571
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 12, 2020
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20190358170
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R3, n, p, L1 and L2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Application
    Filed: August 12, 2019
    Publication date: November 28, 2019
    Inventors: Luis Brito, Delai Chen, Gabriel Grant Gamber, Andrew Geall, Kevin Love, Thomas Zabawa, Frederic Zecri
  • Patent number: 10426737
    Abstract: This invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R3, n, p, L1 and L2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: October 1, 2019
    Assignee: Novartis AG
    Inventors: Luis Brito, Delai Chen, Gabriel Grant Gamber, Andrew Geall, Kevin Love, Thomas Zabawa, Frederic Zecri
  • Patent number: 10179172
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: January 15, 2019
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Publication number: 20180290965
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 11, 2018
    Inventors: Luis Brito, Delai Chen, Gabriel Grant Gamber, Andrew Geall, Kevin Love, Thomas Zabawa, Frederic Zecri
  • Patent number: 10059655
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, n and p are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: August 28, 2018
    Assignee: Novartis AG
    Inventors: Luis Brito, Delai Chen, Gabriel Grant Gamber, Andrew Geall, Kevin Love, Thomas Zabawa, Frederic Zecri